Argen-X - Asset Resilience Ratio

Latest as of December 2025: 10.93%

Argen-X (1AE) has an Asset Resilience Ratio of 10.93% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Argen-X short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

€948.75 Million

≈ $1.11 Billion USD Cash + Short-term Investments

Total Assets

€8.68 Billion

≈ $10.15 Billion USD All company assets

Resilience Assessment

Moderate

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how Argen-X's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Argen-X.

Liquid Assets Composition Over Time

This chart breaks down Argen-X's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore investment intensity of Argen-X to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€948.75 Million	10.93%
Total Liquid Assets	€948.75 Million	10.93%

Asset Resilience Insights

Moderate Liquidity: Argen-X has 10.93% of assets in liquid form.
While adequate for normal operations, this level may limit flexibility during economic stress.
The company has significant short-term investments, indicating active treasury management.

Argen-X Industry Peers by Asset Resilience Ratio

Compare Argen-X's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Tubize-Fin BR:TUB	Biotechnology	2.50%
Dianthus Therapeutics Inc. NASDAQ:DNTH	Biotechnology	63.98%
Tango Therapeutics Inc NASDAQ:TNGX	Biotechnology	62.24%
Damora Therapeutics, Inc. NASDAQ:DMRA	Biotechnology	0.00%
Wecome Pharmaceutical Co Ltd SHE:300878	Biotechnology	0.67%
Tectonic Therapeutic, Inc. NASDAQ:TECX	Biotechnology	86.66%
Relmada Therapeutics Inc NASDAQ:RLMD	Biotechnology	95.25%
MediWound Ltd F:M8W	Biotechnology	56.04%

Annual Asset Resilience Ratio for Argen-X (2016–2025)

The table below shows the annual Asset Resilience Ratio data for Argen-X.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	10.93%	€948.75 Million ≈ $1.11 Billion	€8.68 Billion ≈ $10.15 Billion	-19.37pp
2024-12-31	30.29%	€1.88 Billion ≈ $2.20 Billion	€6.20 Billion ≈ $7.25 Billion	+5.39pp
2023-12-31	24.90%	€1.13 Billion ≈ $1.32 Billion	€4.54 Billion ≈ $5.31 Billion	-19.51pp
2022-12-31	44.41%	€1.39 Billion ≈ $1.63 Billion	€3.13 Billion ≈ $3.66 Billion	+9.25pp
2021-12-31	35.16%	€1.00 Billion ≈ $1.17 Billion	€2.85 Billion ≈ $3.33 Billion	+0.95pp
2020-12-31	34.20%	€635.36 Million ≈ $742.80 Million	€1.86 Billion ≈ $2.17 Billion	-35.88pp
2019-12-31	70.08%	€1.00 Billion ≈ $1.17 Billion	€1.43 Billion ≈ $1.68 Billion	+21.07pp
2018-12-31	49.01%	€283.53 Million ≈ $331.48 Million	€578.46 Million ≈ $676.28 Million	+3.48pp
2017-12-31	45.54%	€168.91 Million ≈ $197.47 Million	€370.91 Million ≈ $433.63 Million	+39.08pp
2016-12-31	6.46%	€6.83 Million ≈ $7.99 Million	€105.77 Million ≈ $123.66 Million	--

pp = percentage points

About Argen-X

F:1AE Germany Biotechnology

Market Cap

$62.44 Billion

€53.41 Billion EUR

Market Cap Rank

#658 Global

#139 in Germany

Share Price

€858.80

Change (1 day)

+0.28%

52-Week Range

€566.40 - €910.00

All Time High

€910.00